Mapping the Epitopes of a Neutralizing Antibody Fragment Directed against the Lethal Factor of *Bacillus anthracis* and Cross-Reacting with the Homologous Edema Factor

Philippe Thullier¹, Arnaud Avril¹, Jacques Mathieu², Christian K. Behrens³, Jean-Luc Pellequer⁴, Thibaut Pelat¹*

¹Unité de Biotechnologie des Anticorps, et des Toxines, Institut de Recherche Biomédicale des Armées, La Tronche, France, ²Département de Microbiologie, Institut de Recherche Biomédicale des Armées, La Tronche, France, ³Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis, France, ⁴Service de Biochimie et Toxicologie Nucléaire, CEA, IBEB, Bagnols-sur-Céze, France

Abstract

The lethal factor (LT) of *Bacillus anthracis*, composed of the protective antigen (PA) and the lethal factor (LF), plays an essential role in anthrax pathogenesis. PA also interacts with the edema factor (EF, 20% identity with LF) to form the edema toxin (ET), which has a lesser role in anthrax pathogenesis. The first recombinant antibody fragment directed against LF was scFv 2LF; it neutralizes LT by blocking the interaction between PA and LF. Here, we report that scFv 2LF cross-reacts with EF and ET, and present an in silico method taking advantage of this cross-reactivity to map the epitope of scFv 2LF on both LF and EF. This method identified five epitope candidates on LF, constituted of a total of 32 residues, which were tested experimentally by mutating the residues to alanine. This combined approach precisely identified the epitope of scFv 2LF on LF as five residues (H229, R230, Q234, L235 and Y236), of which three were missed by the consensus epitope candidate identified by pre-existing in silico methods. The homolog of this epitope on EF (H253, R254, E258, L259 and Y260) was experimentally confirmed to constitute the epitope of scFv 2LF on EF. Other inhibitors, including synthetic molecules, could be used to target these epitopes for therapeutic purposes. The in silico method presented here may be of more general interest.

Introduction

In 2001, the intentional release of anthrax spores through the U.S. postal system confirmed that *Bacillus anthracis* can cause high morbidity and mortality, despite the use of powerful antibiotic and resuscitation techniques. The pathogenesis of *B. anthracis* is largely due to a tripartite protein complex consisting of a component binding cellular receptors, the protective antigen (PA), and two catalytic components, the lethal factor (LF) and the edema factor (EF). PA and LF combine to form the lethal toxin (LT), and PA and EF combine to form the edema toxin (ET). However, only LT is recognized as being essential for anthrax pathogenesis. PA and LF combine to form the lethal toxin (LT), and PA and EF combine to form the edema toxin (ET). However, only LT is recognized as being essential for anthrax pathogenesis. PA and EF combine to form the edema factor (EF, 20% identity with LF) to form the edema toxin (ET), which has a lesser role in anthrax pathogenesis. The first recombinant antibody fragment directed against PA was raxibacumab for the treatment of inhalational anthrax [14]. However, concerns have been raised about the use of anti-PA antibodies alone [15], because it was feared that PA could be naturally or voluntarily modified so as to escape binding by anti-PA antibodies while retaining its biological activity [16]. Consequently anti-LF antibodies have also been considered for anthrax therapy [15]. Another possible advantage of such antibodies is that they could potentially synergize with anti-PA antibodies [17–20].

For antibiotic treatments of anthrax to be effective, they must be administered rapidly after infection [7] as lethal amounts of anthrax toxins are quickly secreted into the bloodstream. Antibiotic efficacy is also limited by the existence of *B. anthracis* antibioresistance [8–10]. However, it was demonstrated in animal models of anthrax that the passive transfer of neutralizing antibodies directed against either PA or LF can improve the outcome of the disease [11]. Consequently, considerable efforts have been devoted, since 2001, to the development of recombinant antibodies to be used to complement antibiotic therapy (for a review, see [12–13]), and they resulted in the recent FDA approval of raxibacumab for the treatment of inhalational anthrax [14]. However, concerns have been raised about the use of anti-PA antibodies alone [15], because it was feared that PA could be naturally or voluntarily modified so as to escape binding by anti-PA antibodies while retaining its biological activity [16]. Consequently anti-LF antibodies have also been considered for anthrax therapy [15]. The first recombinant anti-LF antibody fragment, scFv 2LF, was isolated using an original strategy, based on the construction of phage-displayed libraries from immunized macaques (*Macaca fascicularis*). Macaque and human antibodies are similar and, if
Results

ScFv 2LF cross-reacts with EF and cross-neutralizes ET

In ELISA, and in western blot under reducing conditions, scFv 2LF reacted with both EF and LF (figure 1). The reactivity under reducing conditions indicated that the scFv 2LF epitopes on LF and EF are essentially linear. In a Biacore experiment, the affinity of scFv 2LF for EF was found to be 5 nM (figure 2), which is 5-fold lower than the affinity of scFv 2LF for LF (1.02 nM) [18]. This difference indicates that the epitopes of scFv 2LF on LF and EF are not strictly identical.

The capacity of scFv 2LF to neutralize ET was tested in vivo. Twenty μg of edema toxin (ET) injected into mouse footpads caused edema (figure 3A, left panel), culminating at the 12th hour after injection and returning to normal after 108 hours (figure 3B). The edema was not reduced by premixing 2 μg of IgG-2LF with 20 μg ET. However, premixing 5 μg of IgG 2LF with 20 μg ET resulted in the edema being 25% smaller than that caused by ET alone, and the duration of edema (60 h vs. 108 h) being 45% shorter (figure 3A, middle panel, and figure 3B). Ten μg of IgG 2LF pre mixed with 20 μg ET completely inhibited edema formation (figure 3A, right panel, and figure 3B), and injection of PBS only did not induce edema. These data demonstrate that, in addition to neutralizing LT, scFv 2LF also neutralizes ET.

Identification of epitope candidates by a new in silico method

ScFv 2LF blocks the interaction between LF and PA so that its epitope is presumably located in the N-terminal domain of LF, LFN [18]. Also, scFv 2LF cross-reacts with EF and LF, so its epitope is presumably highly conserved between the two proteins. To interact with an antibody, an epitope has indeed to be exposed to the solvent. Regions highly conserved between LFN and its homolog, the N-terminal domain of EF (EFN), were thus considered to be epitope candidates if they were exposed to the solvent. An in silico method was designed to search for such regions, and its main features were that (i) it was based on a sliding window of five residues, corresponding to the lengths of most epitopes, and residues constituting the extremities of candidate sequences were analyzed in detail (ii) the mean identity between the LFN and EFN sequences was calculated as equal to 35% (figure 4), and this value was used as a threshold, above which regions were selected as candidates if they appeared to be exposed to the solvent (iii) the solvent exposure of candidates was verified statistically.

Starting from the N-terminus, the first region exposed to the solvent and conserved between LFN and EFN is located between positions 96 and 102 (figure 5), as it presents 56% identity. Residue 96 is an alanine, thus it is unlikely to participate significantly in the scFv 2LF binding and it was excluded from the candidate region. Position 103 was added as the corresponding residues in LF (K103) and EF (N103) are exposed to the solvent. The first epitope candidate was thus refined as LF(97–103) and its mean solvent exposure was 53% (table 1).

The second selected candidate region is located between residues 136 and 142, and its percentage identity is 57% (figure 5). Residue K143 was added to this candidate region as it is exposed on LF. The second candidate region retained for further testing was thus LF(136–143), with a mean solvent exposure of 47% (table 1).

The region between LF residues 180 and 184 shares 60% identity with EF, and is exposed to the solvent on both proteins (figure 5). It was refined as LF(178–184), as residues K178 and N179 were added to compensate for the lack of homologs on EF. The mean solvent exposure of LF(178–184) is 52% (table 1).

The region located between 227 and 237 is very similar in LFN and EFN (73%), and exposed to the solvent (figure 5). Because residue 237 is an alanine, only the region between residues 227 and 236 was retained for further study. It was divided into two regions, LF(227–231) and LF(231–236), to limit the number of residues needing to be tested in the following steps of the study. The mean solvent exposures of LF(227–231) and of LF(231–236) are 48% and 44%, respectively (table 1).

Five regions, LF(97–103), LF(136–143), LF(178–184), LF(227–231) and LF(231–236), were thus selected as epitope candidates and their mean solvent exposure is 48.1%. The rest of the LFN and EFN regions sharing an identity greater than 35% had a mean solvent exposure of 19.7%, which is significantly lower (p<0.0001) than the selected regions. The five selected LF regions were thus confirmed as epitope candidates; they are constituted of 32 residues, thus far less than the 261 residues constituting LFN.

Evaluation of the epitope candidates by alanine shaving

If the mutation to alanine (or “shaving to alanine”) of a region selected as an epitope candidate reduced the binding of the mutated LF to scFv 2LF, compared to the unmutated LF, the region was selected for subsequent analysis.

First, it was verified that the unmutated LF produced in our laboratory had a reactivity for scFv 2LF (k= 2.3×10⁻⁴ s⁻¹)
The residues of region LF(97–103) were substituted with alanine and the interaction between the mutated LF and scFv 2LF was tested. The observed $k_d$ was $1.32 \times 10^{-4}$ s$^{-1}$ (figure 6A), thus equivalent to the value observed for the unmutated LF, so that this region was not studied further. Similarly, mutating the residues of region LF(136–143) to alanine led to a $k_d$ of $3 \times 10^{-4}$ s$^{-1}$ (figure 6A), and therefore this second epitope candidate was also rejected. Substitution of the residues of LF(178–184) and of LF(231–236) caused a complete loss of reactivity with scFv 2LF. It was verified that these two variants still reacted with the anti-LF polyclonal antibodies (figure 7), showing that they had been immobilized on the sensorchip and that the loss of reactivity with scFv 2LF was not an artefact. These two regions were thus selected as candidates. Mutation of LF(227–231) to alanine reduced the reactivity with scFv 2LF to a $k_d$ of $1.26 \times 10^{-3}$ s$^{-1}$; this result suggested that LF(227–231) contributes to the interaction with scFv 2LF but that it is not essential for this interaction, and it was included in subsequent evaluations. Thus, alanine shaving identified three regions, LF(178–184), LF(227–231) and LF(231–236), constituted of 17 residues, as candidates to be further studied by alanine scanning. These three regions are close to each other on the three-dimensional structure of LF (figure 6B).

Precise identification of the epitope on LF and EF

Each of the residues constituting LF(178–184), LF(227–231) and LF(231–236) were individually mutated to (“scanned to”) alanine. The mutations of residues H229, R230, Q234, L235 and Y236 weakened the binding between LF and scFv 2LF, as the corresponding values of $k_d$ were at least 3-fold lower than that of the unmutated sequence (figure 8 and table 2). Mutation to alanine of the other residues constituting these three regions did not substantially modify LF reactivity. The LF variant in which H229, R230, Q234, L235 and Y236 were all replaced with alanine reacted with scFv 2LF with a $k_d$ of $1.32 \times 10^{-4}$ s$^{-1}$ (figure 6A).

Figure 1. Evaluation of the reactivity of scFv 2LF with EF by ELISA and western blot. A/ Reactivity of scFv 2LF with EF in ELISA. Reactivity of scFv 2LF with EF is represented in blue, and LF (red) and KLH (green) were used as positive and negative controls, respectively. ScFv 2LF reacted with EF, though less strongly than with LF at high scFv concentrations. B/ Reactivity of scFv 2LF with EF in western blots under reducing conditions (lower part). EF (5, 2 and 1 μg/ml in lanes 4, 5 and 6, respectively) and LF as a positive control (5, 2 and 1 μg/ml in lanes 1, 2 and 3, respectively) were separated by SDS-PAGE electrophoresis (upper part) and their sizes verified to be 90 kDa by separation under reducing conditions. ScFv 2LF reacted similarly with EF and LF under reducing conditions. doi:10.1371/journal.pone.0065855.g001
alanine did not bind scFv 2LF, but it was verified that it still reacted with the anti-LF polyclonal antibodies (figure 9), demonstrating that the scFv 2LF epitope on LF is constituted by LF(229–230) plus LF(234–236). This epitope is linear as expected, but discontinuous.

We tested whether the homolog of this epitope in EF constitutes the epitope of scFv 2LF on EF. For this, a recombinant EF was produced in our laboratory and confirmed to present an reactivity with scFv 2LF similar to that of the commercially available EF (kd = 5.1 \times 10^{-14}\text{ s}^{-1}, table 2). The homologs of LF(229–230) and of LF(234–236) were identified by sequence alignment (figure 4) as EF(253–254) and EF(258–260), respectively. These five residues were all mutated to alanine and the mutated EF was not recognized by scFv 2LF but it reacted with the anti-LF polyclonal antibodies, showing that it retained its general conformation (figure 9). The epitope of scFv 2LF on EF is thus EF(253–254) plus EF(258–260).

Identification of the epitope candidates by existing \textit{in silico} methods

Twelve \textit{in silico} prediction methods, available through web servers or stand-alone programs, were used to map on LF the epitope of scFv 2LF (figure 10). To be in a consensus epitope, a residue must have been predicted as part of the epitope by at least six of the 12 methods. Twelve consensus epitopes were identified: LF(27–35), LF(49–55), LF(86–91), LF(98–104), LF(109–116), LF(124–125), LF(136–139), LF(164–169), LF(176–188), LF(191–210), LF(227–232) and LF(252–261), including a total of 98 residues. Although this consensus region was large, it did not include three (LF(254–236)) of the five residues demonstrated in the present study as constituting the epitope.

Discussion

The scFv 2LF was isolated from a phage-displayed library built from a macaque immunized with the LF sub-unit of the lethal anthrax toxin (LT). It binds LF and neutralizes LT by blocking the interaction between its two components, LF and PA [18]. Here, we show that scFv 2LF also binds EF (20% identity with LF), a component of the edema toxin (ET), constituted of EF and PA. An IgG was derived from scFv 2LF and was shown to neutralize ET \textit{in vivo} (figure 3). The scFv 2LF was previously showed as competing with PA for the interaction with LF, and it was hypothesized that it also competes with PA for the interaction with EF. Because EF and LF interact with PA through their amino-terminal domains, LF\textsubscript{N} and EF\textsubscript{N}, it was also hypothesized that the epitopes of scFv 2LF are located in these domains [4–6]. These epitopes were expected to be well conserved but not identical, because the KD characterizing the interaction between scFv 2LF and EF is about 5-fold less favorable than the KD characterizing the interaction between scFv 2LF and LF.

An \textit{in silico} analysis was used to search for epitope candidates, defined as LF\textsubscript{N} and EF\textsubscript{N} regions exposed to the solvent and presenting a high degree of identity. The degree of identity was averaged over a sliding window of five residues, a common size for an epitope, and regions with identity greater than the mean identity between LF\textsubscript{N} and EF\textsubscript{N} were selected. Five epitope candidates totaling 32 amino acids were thereby identified in the candidate domain, LF\textsubscript{N}, composed of 261 amino acids. This elimination of 87% of the residues greatly facilitated the subsequent experimental investigations, based on mutations to alanine.

The performance of the \textit{in silico} method developed here was compared with that of 12 existing methods. The consensus epitope candidates (the epitope candidates indicated by at least half of these methods) consisted of 98 amino acids, thus was three times larger than the epitope candidates identified by our analysis. Four
out of five epitope candidates (LF(97–103), LF(136–143), LF(178–184), and LF(227–231)) identified in the present in silico study overlap with these consensus epitope candidates. Regarding the fifth epitope candidate identified by our analysis, LF(231–236), only residues 231 and 232 were among the consensus epitope candidates. Therefore, the consensus approach missed LF(234–236) though it constitutes three of the five residues of the epitope. Only four of the twelve pre-existing methods indicated LF(234–236) as epitope candidate; these comparisons highlight the usefulness of the in silico analysis presented here.

Alanine shaving [30] and alanine scanning [27] are complementary approaches to determine experimentally which regions are involved in protein-protein interactions [31–32]: alanine shaving identifies regions containing an epitope, whereas alanine scanning maps precisely the epitope. Here, alanine shaving was utilized to test the five epitope candidates selected by the in silico study. Shaving LF(178–184) and LF(231–236) completely abolished the interaction with scFv 2LF, and shaving LF(227–231) partially reduced the interaction. In these three regions, alanine scanning identified five residues involved in the interaction with scFv 2LF: H229, R230, Q234, L235 and Y236. The simultaneous mutation of these five amino acids to alanine completely abolished LF reactivity with scFv 2LF, demonstrating that they constitute the epitope of scFv 2LF on LF. This epitope partially corresponds to the α helix 10, localized in the LF(231–236) region. Alanine scanning showed that LF(178–184) has no direct role in the interaction between LF and scFv 2LF, even though this region was tested positively by alanine shaving. It is possible that LF(178–184) contributes to the conformation of α helix 10, so that its role in scFv 2LF binding is indirect. This discordance between results obtained by alanine shaving and scanning exemplify that alanine scanning is not only useful for precise epitope mapping, but also necessary to confirm the results of alanine shaving.

Three of the amino acids constituting the scFv 2LF epitope, Q234, L235 and Y236, are included in the LF(231–236) region, and alanine shaving of this region completely abolished the interaction with scFv 2LF. The two other residues, H229 and R230, are located within the LF(227–231) region, whose shaving only reduced the strength of the interaction, so that their role is likely to be less important.

The homolog on EF of the scFv 2LF epitope in LF was localized by sequence alignment as EF(253–254) and EF(258–260). The mutation to alanine of these two regions confirmed that they constitute the scFv 2LF epitope of EF. The residues H229, R230, L235 and Y236, part of the scFv 2LF epitope on LF, are strictly...
conserved in EF, respectively at positions 253, 254, 259 and 260. The glutamine residue at position 234 in LF corresponds to a glutamic acid residue at position 258 in EF; physicochemical properties of these two amino-acids differ only slightly but these differences presumably explain the 5-fold weaker interaction of scFv 2LF with EF than with LF.

If no epitope candidate had been tested positively by mutations to alanine, a second series of candidates would have been defined. For this, the mean exposure of residues constituting LFN (29%) would have been utilized as the solvent exposure threshold, in addition to the similarity threshold. These two thresholds, each defined as a mean value characterizing the antigens, would have identified five additional regions as epitope candidates, constituted of a total of 25 residues, and these regions would have been tested similarly than the first series.

Our first attempt to map the scFv 2LF epitope utilized five synthetic peptides corresponding to the candidates selected by the in silico analysis. Their reactivity with 2LF was tested by ELISA. The peptide corresponding to LF(97–103) was the only peptide that bound to the 2LF antibody, but it did not compete with LF for scFv 2LF binding (data not shown). For this reason, we used a different approach involving mutagenesis techniques guided by the same in silico results. As reported above, the mutagenesis experiments gave different results than the identification of LF(97–103) as epitope. This example illustrates how soluble peptides may present conformations different than those existing in the context of whole proteins, and consequently be misleading for epitope mapping (also see [20] for a discussion of peptide-antibody interactions). It also indicates that epitope mapping with peptides should be confirmed by competition experiments, which is not always the case in published studies.

Recently a crystal structure consisting of a PA dimer bound to LFN has been resolved, allowing identification of the role of each residue involved in the PA/LF interaction [33]. The hydrophobic residues L188, Y223, H229, V232, L235 and Y236 of LF are closely involved in an interaction with an hydrophobic region of PA. In particular, Y236 appears to be essential by forming an hydrogen-bonding network with PA residues. Thus, targeting

![Figure 4. Alignment of the sequences of LFN and EFN, and prediction of their secondary structures according to the LF 3D-structure (1J7N). The $\alpha$ helixes (1 to 12) are colored in red and $\beta$ strands (1 to 4) in yellow. The residues that are identical, very similar and different between LFN and EFN are highlighted in the EFN sequence in dark gray, light gray and white, respectively. The five linear regions identified as epitope candidates are indicated in blue, underlined and numbered: region 1 is LF(97–103), region 2 is LF(136–143), region 3 is LF(178–184), region 4 is LF(227–231) and region 5 is LF(232–236). The residues of LFN constituting the scFv 2LF epitope are indicated in bold.](image_url)

doi:10.1371/journal.pone.0065855.g004

### Table 1. Mean identity between each epitope candidate in LF and the homologous region in EF, and mean solvent exposure of each epitope candidate.

| Epitope candidate | Length | Mean identity between the amino-acid sequence and the homologous region in EF (%) | Mean solvent exposure (%) |
|-------------------|--------|---------------------------------------------------------------------------------|--------------------------|
| LF(97–103)        | 7      | 57                                                                              | 53                       |
| LF(136–143)       | 8      | 50                                                                              | 47                       |
| LF(178–184)       | 7      | 43                                                                              | 52                       |
| LF(227–231)       | 5      | 60                                                                              | 48                       |
| LF(231–236)       | 6      | 67                                                                              | 44                       |

The identities between EF and LF epitope candidates are higher than the threshold, equal to 35%. The calculated mean solvent exposure for the five epitope candidates is 48%.

doi:10.1371/journal.pone.0065855.t001
three (H229, L235, Y236) of the five LF residues essential for the formation of the lethal toxin (figure 11) is sufficient to destabilize that formation. This mechanism differs from the indirect competition by steric hindrance or conformational changes described as the neutralization mechanisms of other antibodies ([17], also see [12] for a review).

In conclusion, we show in the present study that scFv 2LF cross-neutralizes the edema toxin and the lethal toxin, and we describe a

---

**Figure 5. Identification of epitope candidates by the combined analysis of sequence identity and solvent exposure.** The curve in red represents the percentage of identity between LFN and EFN, averaged over a sliding window of five residues. The mean identity between LFN and EFN, 35% (horizontal black line), was chosen as the threshold above which regions were selected as epitope candidates. The curves in green and blue indicate the solvent exposure of LFN and EFN, respectively, averaged over a sliding window of five residues. The five regions of LFN and EFN exposed to the solvent, and sharing an identity higher than the threshold, were selected as epitope candidates. These regions are numbered 1 to 5, and their ends are indicated by vertical black lines.

---

**Figure 6. Biacore experiment to evaluate the reactivity of the five LF variants in which each epitope candidate had been shaved to alanine, and localization of these epitope candidates on a view of the LFN surface.**

A/ The Biacore experiment was performed on a CM5 chip sensitized by scFv 2LF. The curve corresponding to the LF variant in which LF(97–103) was shaved is in purple, the curves corresponding to the shaving of LF(136–143), LF(178–184), LF(227–231) and LF(231–236) are in green, blue, red and orange, respectively. The positive control (commercially available LF) curve is in gray. Only the reactivities of LF variants in which LF(178–184), LF(227–231), LF(231–236) had been shaved were significantly (three-fold or more) lower than the positive control value.

B/ The same color code as in A indicated the five epitope candidates on an apical view of the LFN surface. The three regions selected after alanine shaving, LF(178–184), LF(227–231) and LF(231–236), are proximal. The figure was drawn using Swiss PDB viewer and pov-ray rendering [49].

---

doi:10.1371/journal.pone.0065855.g005
novel *in silico* method based on this cross-reactivity to map its epitopes. This *in silico* method performed better than several existing methods, and may be of more general interest than the present study. The results of the *in silico* method were confirmed and refined by mutations to alanine (alanine shaving followed by alanine scanning), and these methods were found to be more robust than methods based on peptide utilization. The epitopes of scFv 2LF are constituted of LF(229–230) plus LF(234–236) in LF, and of EF(253–254) plus EF(258–260) in EF. These epitopes are located in the region containing helix α10 and it may be possible to target this region with other inhibitors, such as synthetic molecules [34], or by vaccination, to neutralize both LT and ET in order to improve anthrax outcome.

**Materials and Methods**

**Ethics Statement**

All animal studies presented here were specifically approved by the Institut de Recherche Biomédicale des Armées ethics committee under authorization n° 2006/42.1, and were conducted according to European 2010/63/UE guidelines.

**ELISA and western blot**

The cross-reactivity of scFv 2LF with EF was tested by ELISA. Briefly, microtiter plates were coated with 2 μg/ml of EF (List Biological Laboratories, Campbell, CA), while LF (List biological Laboratories) and KLH (Sigma-Aldrich, Saint-Quentin Fallavier, France) were utilized as positive and negative controls respectively. After blocking with PBS-BSA 3%, the plates were incubated with serial dilutions of scFv 2LF. The plates were then washed with PBS-Tween 0.1%, and bound scFv 2LF was detected using a monoclonal anti-polyhistidine antibody conjugated to peroxidase (A7050, Sigma-Aldrich). The reactivity of scFv 2LF with EF was further tested by western blotting under reducing conditions. Three samples of LF and EF were diluted (5, 2 and 1 μg/ml) in RunBlue LDS Sample Buffer (Expedeon, San Diego, USA) with β-mercaptoethanol, heated for 10 min at 80°C and separated by electrophoresis on a 12% SDS-PAGE gel using the Rapid Reducing Running Buffer (Expedeon). The samples were transferred to a polyvinylidene fluoride membrane (Immobilon-Psq, Millipore, Molsheim, France) using a Trans-Blot SD semi-dry electrophoretic transfer cell (Biorad, Marnes-la-Coquette, France). The membrane was blocked, then incubated with a scFv 2LF solution (50 μg/ml). Bound scFv 2LF was revealed with a monoclonal anti-polyhistidine antibody conjugated to peroxidase (A7050, Sigma-Aldrich).

**Affinity measurements**

Affinity constants (K_D) and dissociation constants (k_d) of scFv 2LF for LF, EF and their variants were measured by surface plasmon resonance (SPR) with a Biacore X (Biacore, Uppsala, Sweden) instrument. ScFv 2LF was immobilized at a maximum of 250 resonance units on a CM5 chip (Biacore) via amine coupling. A flow rate of 30 μl/min was maintained during measurements. A minimum of seven dilutions of LF, EF and their variants (220 to 14 nM) in HBS-EP buffer (Biacore) was tested for 1500 s. After each dilution, the chip was regenerated with glycine 1.5 buffer (Biacore), run at 10 μl/min for 30 s. Results were analyzed with the Biaevaluation software (a 1:1 (Langmuir) binding model for K_D measurements, and a 1:1 (Langmuir) dissociation model for k_d).
Table 2. ScFv 2LF dissociation rate constants with each LF variant, measured by Biacore experiments.

| residues | k_d (s^-1) |
|----------|------------|
| 97–103   | 1.32x10^-4 |
| 136–143  | 3x10^-4    |
| 178–184  | /          |
| 227–231  | 1.26x10^-4 |
| 231–236  | /          |
| K178     | 2x10^-4    |
| N179     | 2.12x10^-4 |
| S181     | 3.1x10^-4  |
| D182     | 3.9x10^-4  |
| S183     | 2.9x10^-4  |
| D184     | 1.3x10^-4  |
| P227     | 5.6x10^-4  |
| Q228     | 6x10^-4    |
| H229     | 10x10^-4   |
| R230     | 9.34x10^-4 |
| D231     | 5.3x10^-4  |
| V232     | 5.24x10^-4 |
| L233     | 4.8x10^-4  |
| Q234     | 9.54x10^-4 |
| L235     | 8.95x10^-4 |
| Y236     | 8.55x10^-4 |
| Native LF| /          |
| Native EF| 2.3x10^-4  |

The five residues whose mutation to alanine resulted in a 3-fold, or larger, decrease of the dissociation constant are shown in bold.

doi:10.1371/journal.pone.0065855.t002

measurements). If an LF or EF variant did not interact with scFv 2LF, its presence was verified by a Biacore experiment using anti-LF polyclonal antibodies. For this, the variant was immobilized on a CM5 chip as described above, and serum drawn from the macaque hyper-immunized with LF was used for detection (diluted 1:100 in HBS-EP buffer) while the pre-immune serum (diluted 1:100 in HBS-EP buffer) was used as a control [18].

In vivo neutralization test
ScFv 2LF was reformatted as a full-sized IgG, IgG 2LF, by expression of its variable regions in fusion with human constant regions (Fc) of γ1 and κ isotypes. Human constant regions were preferred to their murine counterparts because the IgG has therapeutic potential, and a human Fc ensures better tolerance. The in vivo neutralization test was adapted from a previous study [35]. The edema toxin (ET) was obtained by mixing equal weights of PA and EF. Twenty-μg of ET, premixed with 0, 2, 5 or 10 μg of IgG 2LF in a final volume of 25 μl in PBS, or 25 μl of PBS alone as a control, were injected into the right rear footpad of five Balb/c mice. The sizes (dorsal/plantar) of the footpads were measured in triplicate, with digital vernier caliper.

Identification of epitope candidates by combined identity and solvent exposure analysis
LF and EF sequences were retrieved under the access numbers P15917 and P40136, respectively. The ends of LFN and EFN were defined in accordance with sequence annotations (LFN begins at residue E27 and EFN begins at residue N64) and the two sequences were aligned with the CLUSTALW tool at the PBIL server (http://phil.univ-lyon1.fr), using standard parameters (figure 4). For each position in LFN, a score of 1 or 0 was attributed when the EFN counterpart residue was identical or different, respectively. When alignment gaps occurred, a score of 0 was attributed to the LF residues having no counterparts in EF. A curve averaging the identity percentage over a window of five residues was calculated to visualize the portions shared between EFN and LFN, as a length of five residues was considered as corresponding to the length of epitopes [36]. X-ray crystallographic structures for LF (1J7N) [4] and EF (1XFV) [37] were retrieved from the Protein Data Bank (www.rcsb.org). The solvent exposure for each residue on LFN and EFN structures was calculated using the ASAView tool [38], then averaged using a sliding window of five amino acids. The three curves representing these three averaged parameters (identity between LFN and EFN, solvent exposure of EF and solvent exposure of LF) are shown in figure 5. Epitope candidates were identified as regions where LFN and EFN identity, averaged on a sliding window of 5 residues, is superior to the mean identity between LFN and EFN, and where solvent exposure is high. The identity between LFN and EFN, the nature and the solvent exposure of each residue were studied individually to determine the ends of regions selected as epitope candidates. Once the epitope candidates were precisely defined, their solvent exposures were statistically tested (unpaired t test, GraphPad Prism 5, La Jolla, CA).

Alanine shaving and scanning
Alanine shaving and scanning are two complementary methods, both consisting of directed mutagenesis of residues to alanine to reduce their side chains to methyl groups; this eliminates the interactions involving the side chains of these residues. Alanine shaving is the replacement of several contiguous amino acids in the antigen, and tests for the presence of an epitope in the corresponding region. When alanine shaving indicates that a region contains an epitope, each of the residues has to be individually mutated to alanine to localize the epitope precisely. It might be remarked that mutation to glycine, which has no side-chain beyond the β-carbon, introduces a conformational flexibility which may indirectly alter the epitope and the affinity, so that mutation to glycine is inappropriate for epitope mapping [29].

Six genes, encoding LF and its variants, in which an epitope candidate had been shaved to alanine, were synthesized (Entelechon, Regensburg, Germany), inserted into the vector pET15B (Merck chemical, Darmstadt, Germany) and expressed as described below. The interaction between a variant and scFv 2LF was regarded as significantly altered if the k_d was more than a three-fold lower than observed with the parental LF. For alanine scanning, each residue was individually mutated to alanine (Entelechon) and the corresponding variants were expressed as described below. If the mutation of a residue to alanine decreased the k_d by more than a three-fold, the mutated residue was regarded as being part of the epitope. All residues identified as composing the epitope were then simultaneously mutated to alanine, and the reactivity of the variant was tested by Biacore. The epitope was confirmed if all immunoreactivity was lost.

Expression and purification of LF, EF and their variants were as described for scFv 2LF [18], except that cytoplasmic extracts were
Figure 8. Biacore experiment to evaluate the reactivity between scFv 2LF and the five LF variants, in which H229, R230, Q234, L235 or Y236 had been individually mutated in alanine, or the LF variant where these five residues had been simultaneously mutated in alanine. A CM5 chip was sensitized with scFv 2LF. LF (control, in grey) and its five variants in which H229 (yellow), R230 (blue), Q234 (red), L235 (green) or Y236 (brown) had been individually mutated in alanine reacted in flux. The LF variant in which these five positions had been simultaneously mutated in alanine is presented in blue. Dilutions of LF and its variants giving an equivalent maximal signal are presented, to allow the comparison of the dissociation phases (after the maximal signal and the artefactual spikes) when dissociation constants are measured (between the 500th and 700th seconds). Values were calculated on several curves for each variant, and are presented on table 2: the five variants with punctual mutations present at least a three-fold more rapid dissociation than the control, and the variant with the five simultaneous mutations presents no reactivity.
doi:10.1371/journal.pone.0065855.g008

Figure 9. Biacore experiment to evaluate the reactivity between anti-LF polyclonal antibodies and LF, EF or their variants in which the epitope of scFv 2LF had been shaved in alanine. A CM5 chip was sensitized with LF (deep blue) or its variant (light blue) in which residues 229, 230, 234, 235 and 236 (corresponding to scFv 2LF epitope on LF) had been simultaneously substituted by alanine. Another CM5 chip was sensitized with EF (red) or its variant (rose) in which residues 253, 254, 258, 259 and 260 (corresponding to scFv epitope on EF) had been simultaneously mutated in alanine. The serum of a macaque drawn before or after immunization with LF was utilized in flux. The serum drawn before immunization did not react with LF nor with EF as expected (in green). The serum drawn after immunization reacted with both variants, though slightly less than with the parental molecules, showing that they had been immobilized on the chip and that their general conformations had been retained despite the shaving.
doi:10.1371/journal.pone.0065855.g009
Figure 10. Results with web-based or stand-alone programs predicting 2LF epitopes. Results of 12 prediction methods used to predict 2LF epitopes are given as letters indicating the predictions and the method (a: BEPITOPE (TURNEE); b: BEPITOPE (TURN33); c: BepiPred; e: Ellipro; g: LEP-LP; h: BCPREDS; j: Epitopia; k: COBEpro; d: CBTOPE; f: Ellipro; i: DiscoTope; l: BEpro). The residues predicted as being part of the epitope are indicated by an “X” above the LFN and EFN alignment. The five epitope candidates identified by the in silico method developed in the present study are indicated with hyphens and numbered.

doi:10.1371/journal.pone.0065855.g010
obtained by sonication (1 min pulses of 6 seconds and 10 Watts, separated by pauses of 1 s) (Vibracell 7240S, Bioblock scientifique, obtained by sonication (1 min pulses of 6 seconds and 10 Watts, Ray crystal structure 3KWV [33]).

Figure 11. Complex between PA and LF as observed in the X-ray crystallography. The α carbons constituting LF are drawn as a gray tube, and PA is represented as its molecular surface (carbon in cyan), and are located on α helix 10. The figure was drawn using VMD [50].

doi:10.1371/journal.pone.0065855.g011

Purity was estimated at 25% and was insufficient for precise measurement of concentrations, which in turn prevented the measurement of the affinity constant ($K_D$). Since the dissociation constant ($k_d$) correlates with binding affinity [36] and its measurement does not depend on concentration values, the present study was based on $k_d$ measurements.

Identification of the epitope candidates by existing in silico methods

In addition to the in silico method developed here, 12 prediction methods available through web servers or stand-alone programs (8 predicting continuous epitopes, 4 predicting discontinuous epitope) were used to identify epitope candidates: BEPITOPE (continuous, Pellequer’s method with TURN33 scale, default settings) [39], BEPITOPE (continuous, Pellequer’s method with TURN33 scale, default settings, [39]), BepiPred (continuous, default settings, [40], Ellipro (continuous, default settings, [41], LEP-LP (continuous, default settings, [42], BCPRDESS (continuous, default settings, [43], Epitopia (continuous, default settings, [44], COBEpRO (continuous, default settings, [45], CBTTOPE (discontinuous, default settings, [46], Ellipro (discontinuous, default settings, [41], Discotope (discontinuous, default settings, [47], BEpRO (discontinuous, default settings, select residues with score ≥0.5 [48]). A consensus epitope was defined as a region for which half of the methods predicted an epitope.

Author Contributions

Conceived and designed the experiments: PT TP. Performed the experiments: PT AA CB JLP TP. Analyzed the data: PT AA JM JLP TP. Contributed reagents/materials/analysis tools: PT CB JLP TP. Wrote the paper: PT JLP TP.

References

1. Mock M, Fouet A (2001) Anthrax. Annu Rev Microbiol 55: 647–671.
2. Moayeri M, Leppla SH (2009) Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med 30: 439–453.
3. Elliott JL, Mogridge J, Collier RJ (2000) A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 39: 6706–6713.
4. Paumier AD, Wong TY, Schwanenbacher R, Renatus M, Petosa G, et al. (2001) Crystal structure of the anthrax lethal factor. Nature 414: 229–233.
5. Petosa C, Collier RJ, Kimpel KR, Leppla SH, Liddington RC (1997) Crystal structure of the anthrax toxin protective antigen. Nature 385: 833–838.
6. Lacy DR, Moorez M, Fouassier A, Collier RJ (2002) Mapping the anthrax protective antigen binding site on the lethal and edema factors. J Biol Chem 277: 3006–3010.
7. Burnett JC, Henchel EA, Schmaljohann AL, Bavari S (2005) The evolving field of biodefense: therapeutic developments and diagnostics. Nat Rev Drug Discov 4: 281–297.
8. Patra G, Vaisaire J, Weber-Levy M, Le Doujet C, Mock M (1998) Molecular characterization of Bacillus strains involved in outbreaks of anthrax in France. In: J Clin Microbiol 36: 3412–3414.
9. Lightfoot N, Scott R, Turnbull B (1990) Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 68.
10. Durmaz R, Doganay M, Sahin M, Percin D, Karahocagil MK, et al. (2012) Molecular epidemiology of the Bacillus anthracis isolates collected throughout Turkey from 1983 to 2011. Eur J Clin Microbiol Infect Dis 31: 2783–2790.
11. Little SF, Ivens BE, Fellow PJ, Friedlander AM (1997) Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65: 5171–5175.
12. Frouille J, 2nd, Thuiller P, Patel T (2011) Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) 3: 1433–1452.
13. Chen Z, Moayeri M, Purcell R (2011) Monoclonal Antibody Therapies against Anthrax. Toxins 3: 1004–1019.
14. Fox JL (2013) Anthrax drug first antibacterial mAb to win approval. Nat Biotechnol 31: 8.
15. Baillie LW (2006) Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol 101: 594–606.
16. Rosovitz MJ, Schuck P, Varughese M, Chopra AP, Mehra V, et al. (2003) Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 278: 30936–30944.

17. Brossier F, Levy M, Landler A, Lafaye P, Mock M (2004) Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 72: 6315–6317.
18. Pelat T, Huest M, Laffly E, Cendemine F, Bottec G, et al. (2007) High-affinity, human-antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 51: 2758–2764.
19. Albrecht MT, Li H, Williamson ED, Lebout CS, Flick-Smith HC, et al. (2007) Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 75: 5425–5433.
20. Chen Z, Moayeri M, Crown D, Emerson S, Gorshkova I, et al. (2009) Novel chimeric/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun 77: 3902–3908.
21. Pelat T, Thuiller P (2009) Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. Mabs 1: 377–381.
22. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc MP, et al. (2008) Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384: 1400–1407.
23. Little SF, Leppla SH, Friedlander AM (1998) Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun 66: 1606–1613.
24. Zhao P, Liang X, Kalbfleisch J, Koo HM, Cao B (2003) Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum Antibodies 12: 129–135.
25. Lim NK, Kim JH, Oh MS, Lee S, Kim SY, et al. (2005) An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect Immun 73: 6547–6551.
26. Storm RB, Wellis-HJ, Nussinov R (2003) Protein functional epitopes: hot spots, dynamics and combinatorial libraries. Curr Opin Struct Biol 11: 364–369.
27. Jin L, Fendly BM, Wellis JA (1992) High resolution functional analysis of antibody-antigen interactions. J Mol Biol 226: 831–865.
28. Thorn KS, Bogan AA (2001) ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions. Bioinformatics 17: 284–285.
29. Moreira IS, Fernandes PA, Ramos MJ (2007) Hot spots—a review of the protein-protein interface determinant amino-acid residues. Proteins 68: 803–812.
30. Jin L, Wells JA (1994) Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting. Protein Sci 3: 2351–2357.
31. Zhang Y, Randuhi S, Teo H, Teo GW, Fan R, et al. (2010) Alanine-shaving mutagenesis to determine key interfacial residues governing the assembly of a nano-cage maxxi-ferritin. J Biol Chem 285: 12078–12086.
32. Morrison KL, Weiss GA (2001) Combinatorial alanine-scanning. Curr Opin Chem Biol 5: 302–307.
33. Feld GK, Thoren KL, Kintzer AF, Sterling HJ, Tang, II, et al. (2010) Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers. Nat Struct Mol Biol 17: 1383–1390.
34. Jiao GS, Kim S, Moayeri M, Gregor-Hernandez L, McKassen L, et al. (2010) Antidotes to anthrax lethal factor intoxication. Part I: Discovery of potent lethal factor inhibitors with in vivo efficacy. Bioorg Med Chem Lett 20: 6850–6853.
35. Kulaibeshtha P, Bhatnagar R (2011) Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Mol Immunol 48: 1958–1965.
36. Pellequer J-L, Van Regenmortel MHV (1993) Affinity of monoclonal antibodies to large multivalent antigens: influence of steric hindrance on antibody affinity constants calculated from Scatchard plots. MI 30: 955–958.
37. Shen Y, Zhukovskaya NL, Guo Q, Florian J, Tang WJ (2005) Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J 24: 929–941.
38. Ahmad S, Gromiha M, Fawarch H, Sarai A (2004) ASAView: database and tool for solvent accessibility representation in proteins. BMC Bioinformatics 5: 51.
39. Oderico M, Pellequer J-L. (2003) BEPTOPE: predicting the location of continuous epitopes and patterns in proteins. JMR 16: 20–22.
40. Larsen JE, Lund O, Nielsen M (2006) Improved method for predicting linear B-cell epitopes. ImmunoRes 2: 2.
41. Ponomarenko J, Bui HH, Li W, Fasseder N, Bourne PE, et al. (2008) ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 9: 514.
42. Chang HT, Liu CH, Pai TW (2008) Estimation and extraction of B-cell linear epitopes predicted by mathematical morphology approaches. J Mol Recognit 21: 431–441.
43. El-Manzalawy Y, Dobbs D, Honavar V (2008) Predicting linear B-cell epitopes using string kernels. J Mol Recognit 21: 243–253.
44. Rubinstein ND, Mayrose I, Martz E, Pupko T (2009) Epitopia: a web-server for predicting B-cell epitopes. BMC Bioinformatics 10: 297.
45. Sweredoski MJ, Baldi P (2009) COBEpro: a novel system for predicting continuous B-cell epitopes. Protein Eng Des Sel 22: 113–120.
46. Ansari HR, Raghava GP (2010) Identification of conformational B-cell Epitopes in an antigen from its primary sequence. ImmunoRes 6: 6.
47. Haste Andersen P, Nielsen M, Lund O (2006) Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci 15: 2558–2567.
48. Sweredoski MJ, Baldi P (2008) PEPTTO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. Bioinformatics 24: 1459–1460.
49. Kaplan W, Littlejohn TG (2001) Swiss-PDB Viewer (Deep View). Brief Bioinform 2: 195–197.
50. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33–38, 27–38.